CYTK Mizuho raised the firm's price target on Cytokinetics to $118 from $100 and keeps an Outperform rating on the shares. The firm updated

CYTK Mizuho raised the firm's price target on Cytokinetics to $118 from $100 and keeps an Outperform rating on the shares. The firm updated the company's model following the Q1 report.